Metformin and clemastine in combination ( DrugBank: Clemastine, Metformin )

---

1 disease

ID	Disease name (Link within this page)	Number of trials
13	Multiple sclerosis/Neuromyelitis optica	1

13. Multiple sclerosis/Neuromyelitis optica

---

Clinical trials : 3,340 /  Drugs : 2,163 - (DrugBank : 383) / Drug target genes : 241 - Drug target pathways : 238

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05131828 (ClinicalTrials.gov)	March 8, 2022	12/11/2021	CCMR Two: A Phase IIa, Randomised, Double-blind, Placebo-controlled Trial of the Ability of the Combination of Metformin and Clemastine to Promote Remyelination in People With Relapsing-remitting Multiple Sclerosis Already on Disease-modifying Therapy	CCMR Two: A Phase IIa, Randomised, Double-blind, Placebo-controlled Trial of the Ability of the Combination of Metformin and Clemastine to Promote Remyelination in People With Relapsing-remitting Multiple Sclerosis Already on Disease-modifying Therapy	Multiple Sclerosis	Drug: Metformin and clemastine in combination;Drug: Placebo	Cambridge University Hospitals NHS Foundation Trust	University of Cambridge	Recruiting	25 Years	50 Years	All	50	Phase 2	United Kingdom